Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AG-013736 (AXITINIB) FOR THE TREATMENT OF METASTATIC RENAL CELL CANCER

NCT00920816 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00920816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00920816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AG-013736 (AXITINIB) FOR THE TREATMENT OF METASTATIC RENAL CELL CANCER
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
August 25, 2009
Completion date
April 29, 2021
Enrollment
492 (actual)
Sites
125

Conditions

As the registry lists them; a condition with its own page is linked.

kidney neoplasms